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Eradicating Polio
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During the past 12 months, poliovirus has been
spreading to states in Nigeria that were previously
free of poliomyelitis. Moreover, global surveillance
for acute flaccid paralysis
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 — involving the genom-
ic sequencing of each wild poliovirus that is detect-
ed — has demonstrated that wild poliovirus geneti-
cally linked to parent viruses in northern Nigeria
has spread to 12 other previously polio-free coun-
tries in sub-Saharan Africa.
Rumors of “contaminated” polio vaccine ignited
a controversy in Kano State, in northern Nigeria, in
mid-2003 and led to the immediate and official sus-
pension of immunization activities. Such rumors —
the substance of which varies from the contamina-
tion of polio vaccine with human immunodeficiency
virus at the time of manufacture to the deliberate ad-
dition of hormones to permanently sterilize young
girls — have plagued the poliomyelitis-eradication
initiative since its beginning in 1988.
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 Shortly after
the suspension of polio-vaccination activities in Ni-
geria, a national commission was set up by the Fed-
eral Ministry of Health to evaluate the safety of the
polio vaccines that were being used, and two differ-
ent state-level commissions were established in
Kano to do the same. By July 31, 2004, all three com-
missions had independently concluded that the po-
lio vaccines were safe, and the governor of Kano re-
launched the vaccination effort.
All countries where poliovirus is endemic pro-
cure polio vaccine through the United Nations Chil-
dren’s Fund (UNICEF), one of the four partners
spearheading the eradication effort, along with the
World Health Organization (WHO), Rotary Inter-
national, and the Centers for Disease Control and
Prevention. These vaccines, purchased from manu-
facturers that are prequalified by the WHO, have
been used safely since well before the polio-eradica-
tion initiative began in 1988. Their use has resulted
in a decrease of more than 99 percent in the inci-
dence of paralytic poliomyelitis in children, from an
estimated 1000 cases per day worldwide in 1988 to
fewer than 3 cases per day in 2003, with a corre-
sponding decrease in the number of countries where
poliovirus is endemic, from 125 to 6 (see Figure).
Some children have received more than 10 doses of
oral poliovirus vaccine during consecutive “nation-
al immunization day” campaigns, with no increase
in the incidence of adverse events, including vac-
cine-associated paralytic polio, which has an esti-
mated incidence of 2 to 4 cases per million births
per year.
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As a result of the suspension of polio-vaccina-
tion activities in Kano, between January 1 and Sep-
tember 1, 2004, infection with wild poliovirus has
been confirmed in 491 paralyzed children in Nige-
ria. This country now accounts for nearly 80 percent
of the global burden of paralytic poliomyelitis. In
2003, the global surveillance system for acute flac-
cid paralysis identified a wild poliovirus linked to
Nigeria in a child from Ghana, a country that had
been free of poliomyelitis since November 2000.
Since then, wild poliovirus has spread both within
Nigeria, to infect persons in 31 of its 37 states, and
across international borders to a total of 12 coun-
tries in sub-Saharan Africa that had been polio-free
(see Figure). In many of these countries, the virus
spread rapidly because, in all but two of them, the
rate of polio-vaccination coverage (the percentage
of children who had received at least three doses of
oral poliovirus vaccine through routine immuniza-
tion services) was estimated to be less than 75 per-
cent (median, 48 percent); the exceptions were
Ghana and Botswana, where the coverage rate was
greater than 90 percent.
In January 2004, the ministers of health of the six
remaining countries where poliovirus is endemic
met in Geneva with the four spearheading organi-
zations involved in the international polio-eradica-
tion effort and declared that they would interrupt the
transmission of wild poliovirus by the end of 2004.
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India, Pakistan, Afghanistan, and Egypt — four of
the six — have made great progress since then: be-
tween January 1 and September 1, the incidence of
poliomyelitis has dropped to its lowest level ever in
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each of these countries, which together now ac-
count for 11 percent of the global burden of the
disease. The current risks in these countries are
those associated with a premature decrease in the
intensity of both surveillance and massive, house-
to-house polio “mop-up” vaccination activities in
the few remaining areas where wild poliovirus has
been detected.
In the two other countries where poliovirus is
endemic, Niger and Nigeria, there is a danger that
efforts will fail to reach more than 90 percent of the
target population with effective vaccine or that the
necessary financial resources will be lacking. An ad-
ditional risk is that efforts to reestablish polio-free
status in the 12 countries to which the virus has
spread will fail. Each July, when the rainy season be-
gins in western and central Africa, the intensity of
transmission of poliovirus increases. With levels of
vaccination coverage well below 50 percent in many
of these countries, the task ahead is substantial.
Five times as many children have been paralyzed by
infection with wild poliovirus in Africa since Janu-
ary 1, 2004, as during the corresponding period in
2003, putting sub-Saharan Africa on the verge of the
largest polio epidemic in recent history.
Planning is therefore under way in 23 western
and central African countries for synchronized na-
tional immunization days in October and Novem-
ber 2004 and again in early 2005 to interrupt the
transmission of wild poliovirus in Africa. The final
eradication of polio hinges on continued govern-
ment commitment in those countries where polio-
virus is endemic and those that are at risk for impor-
tation, as well as on the availability of an additional
$200 million in financial resources for the vaccina-
tion activities required to do the job.
If the campaign is successful and the internation-
al spread of wild poliovirus is contained, at least one
further step will be required to eliminate polio: all
countries that are now using oral poliovirus vaccine
must cease using it after global eradication, in order
to eliminate the risks of paralytic poliomyelitis from
vaccine-associated paralytic polio and circulating
vaccine-derived poliovirus.
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 First identified in 1999
in Hispaniola and then found in the Philippines, in
Madagascar, and retrospectively in Egypt, circulat-
ing vaccine-derived poliovirus is now known to be
another challenge to polio eradication, especially
where routine immunization coverage is low and
surveillance for acute flaccid paralysis weak, because
of its capacity to cause outbreaks of paralytic disease.
After transmission of wild poliovirus has been in-
terrupted, such vaccine-derived virus will therefore
be a source of paralytic disease, and this risk of
transmission will continue as long as the oral polio-
virus vaccine remains in use.
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Other long-term, albeit small, risks include the
potential reintroduction into the community of a
vaccine-derived poliovirus from prolonged excre-
tion by a person with a severe primary immunode-
ficiency syndrome and the reintroduction of a wild
or Sabin poliovirus from a laboratory or vaccine-pro-
duction facility. With the current knowledge about
these risks, the continued global surveillance for po-
 
Figure. Countries Reporting Cases of Paralytic Poliomyelitis due to Wild Poliovirus, January 1, 2003, to September 1, 2004.
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liovirus, and the availability of a vaccine stockpile in
case of an outbreak, however, countries are increas-
ingly equipped to decide on the most appropriate
vaccination policies after the eradication of polio.
 
From the Polio Eradication Initiative, World Health Organization,
Geneva.
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Should the law let patients sue health plans for dam-
ages when plans deny coverage and bad results en-
sue? A June ruling by the U.S. Supreme Court has
returned this question to the forefront of the na-
tion’s political agenda. The decision, in 
 
Aetna
 
 v. 
 
Davi-
la,
 
1
 
 immunized employer-sponsored health plans
against damage suits for wrongful denial of cover-
age. It voided statutes in 10 states that expressly al-
lowed such suits and barred courts everywhere from
permitting such claims to go forward under judge-
made law. Consumer advocates, congressional
Democrats, and their party’s presidential nominee,
John Kerry, vowed legislative action to end managed
care’s immunity, setting up a struggle with the Bush
administration, which backed the industry in 
 
Aetna
 
v. 
 
Davila
 
. What does this mean for patients and phy-
sicians?
Americans with private health insurance typi-
cally obtain their coverage through the workplace,
under the terms of a convoluted federal statute that
was not designed with medical care in mind. Con-
gress passed this law, known as the Employee Re-
tirement Income Security Act (ERISA), in 1974 to
protect workers’ retirement income in the wake of
a series of pension-fund scandals that were the En-
ron and WorldCom affairs of their day. Because
ERISA supplanted wide areas of state law, it nulli-
fied most rules governing workplace-based health
insurance.
The rise of managed care in the 1980s exposed
this regulatory void, as aggrieved patients sought
remedies and found that they had none. By the mid-
1990s, the conventional wisdom, supported by sev-
eral court rulings,
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 held that managed-care health
plans could not be sued for withholding coverage or
care. The public’s ire over insurers’ impunity helped
to fuel the late-1990s backlash against managed
care. Market pressures and the prospect of a “Pa-
tients’ Bill of Rights” pushed health plans away
from intrusive cost-control methods, including the
refusal to cover medically prescribed treatments.
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Interest-group gridlock stymied congressional
efforts to enact a “Patients’ Bill of Rights,” but fed-
eral judges began to reinterpret ERISA in such a way
as to shrink the legal void. In the late 1990s, lower
courts allowed patients to sue health plans for mal-
practice committed by plan physicians, and in 2002,
the Supreme Court upheld laws in more than 40
states mandating independent medical review when
plans deny coverage.
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 Since 2000, a number of low-
er courts have permitted damage suits against plans
for withholding care. When the Supreme Court
agreed to consider 
 
Aetna
 
 v. 
 
Davila,
 
 many observers
expected the justices to craft an obituary for man-
aged care’s immunity from such claims.
Instead, the Court fully restored this immunity,
striking down a Texas law authorizing such suits.
As a candidate for president four years ago, former
Texas governor George Bush pointed to this law,
passed on his watch, as proof of his commitment to
patients’ rights. But last December, the Bush admin-
istration asked the justices to reject the law, warning
that it and similar laws in other states would push
health care costs skyward.
The evidence, however, suggests that empower-
ing patients to seek damages for coverage denied
Back to the ’90s — The Supreme Court Immunizes 
Managed Care
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